ScholarIQanswers from OpenAlex
Swedish Orphan Biovitrum (United States)
InstitutionResearch output, impact & collaborations
Swedish Orphan Biovitrum (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Swedish Orphan Biovitrum (United States)?
ScholarIQrecord summary
Swedish Orphan Biovitrum (United States) is a research organisation in Waltham, US. OpenAlex records 81 works and 24,070 citations for it.
How many works does Swedish Orphan Biovitrum (United States) have?
ScholarIQindexed works
Swedish Orphan Biovitrum (United States) has 81 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Swedish Orphan Biovitrum (United States) have?
ScholarIQcitation count
Swedish Orphan Biovitrum (United States) has 24,070 citations in the OpenAlex counts ScholarIQ stores.
What is the average h-index at Swedish Orphan Biovitrum (United States)?
ScholarIQavg h-index
Swedish Orphan Biovitrum (United States) has an average h-index of 27 in OpenAlex.
What is the ROR of Swedish Orphan Biovitrum (United States)?
ScholarIQror
The ROR for Swedish Orphan Biovitrum (United States) is on the source record.
What is the OpenAlex record for Swedish Orphan Biovitrum (United States)?
ScholarIQopenalex
The OpenAlex for Swedish Orphan Biovitrum (United States) is on the source record.
Who are the most-cited researchers behind Swedish Orphan Biovitrum (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Swedish Orphan Biovitrum (United States)?
ScholarIQmost cited works
Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors
A. Taamma, J. L. Misset, M. Riofrio, C. Guzmán, Étienne Brain, Luis López Lázaro, Hilde Rosing, José Jimeno, Esteban Cvitkovic
Erythema nodosum: Etiologic and predictive factors in a defined population
Carlos Garcı́a-Porrúa, Miguel Á. González‐Gay, Manuel Vázquez‐Caruncho, Luis López Lázaro, Mercedes Lueiro, María Lameiras Fernández, Javier Alvarez‐Ferreira, Ramón M. Pujol
Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies
Sandrine Faivre, Stéphanie Chièze, Catherine Delbaldo, Nora Ady-vago, Cecilia Guzmán, Luis López Lázaro, Stéphanie Lozahic, José Jimeno, Fernando Pico, Jean Pierre Armand, José A. López-Martín, Éric Raymond
Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin
Ch. van Kesteren, M. M. M. de Vooght, Luis López Lázaro, Ron A. A. Mathôt, Jan H.M. Schellens, José Jimeno, Jos H. Beijnen
Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer
Jeany M. Rademaker-Lakhai, Simon Horenblas, W. Meinhardt, Ellen Stokvis, Theo M. de Reijke, José Jimeno, Luis López Lázaro, José A. López-Martín, Jos H. Beijnen, Jan H.M. Schellens
How much of the research on Swedish Orphan Biovitrum (United States) is open access?
ScholarIQopen access share
27%OPEN ACCESS